Top

Published in:

01-08-2011

Malignant Pleural Mesothelioma

Authors: Siva Raja, Sudish C. Murthy, David P. Mason

Published in: Current Oncology Reports | Issue 4/2011

Abstract

Malignant pleural mesothelioma (MPM) is a relatively rare thoracic malignancy accounting for about 2000–3000 new cases per year. This cancer has been increasing in incidence and is strongly associated with asbestos exposure. Also, it is characterized by insidious growth and clinical presentation at an advanced stage of disease. In the past, the treatment of this disease was limited to marginally effective chemotherapy and morbid surgery. This review explores the clinical presentation of MPM, its diagnostic approach and the relevant and recent studies that define the role of chemotherapy, radiation, and various surgical options. Currently, even with aggressive surgical interventions and multimodality strategies, cure remains elusive, although life prolongation has been achieved. Additionally, promising new therapies and interventions that are currently being studied are introduced in this review.

Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9(2–3):147–57.PubMedCrossRef

Milne JE. Thirty-two cases of mesothelioma in Victoria, Australia: a retrospective survey related to occupational asbestos exposure. Br J Ind Med. 1976;33(2):115–22.PubMed

Greenberg M, Davies TA. Mesothelioma register 1967–68. Br J Ind Med. 1974;31(2):91–104.PubMed

Chirieac LR, Corson JM. Pathologic evaluation of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):121–4.PubMedCrossRef

Belli C, Anand S, Tassi G, Fennell D, Mutti L. Translational therapies for malignant pleural mesothelioma. Expert Rev Respir Med. 2010;4(2):249–60.PubMedCrossRef

Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989;7(8):1157–68.PubMed

Lee ST, Ghanem M, Herbertson RA, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imag Biol. 2009;11(6):473–9.CrossRef

Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126(1):11–6.PubMedCrossRef

Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

10.

Schouwink JH, Kool LS, Rutgers EJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg. 2003;75(6):1715–8. discussion 1718–1719.PubMedCrossRef

11.

Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129(6):1364–70.PubMedCrossRef

12.

Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80(6):1988–92. discussion 1992–1983.PubMedCrossRef

13.

Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120(1):128–33.PubMedCrossRef

14.

Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.PubMedCrossRef

15.

Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889–905.PubMedCrossRef

16.

Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):177–87.PubMedCrossRef

17.

•Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg. Summer 2009;21(2):132–148. This article clearly explains the technical nuances of performing extrapleural pneumonectomies and pleurectomy/decortication. PubMedCrossRef

18.

••Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–626, 626 e621-623. This study showed that both extrapleural pneumonectomies and pleurectomy/decortication have comparable outcomes for the treatment of mesothelioma.

19.

Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128(1):138–46.PubMedCrossRef

20.

Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg. 1997;11(2):210–3.PubMedCrossRef

21.

Balduyck B, Trousse D, Nakas A, Martin-Ucar AE, Edwards J, Waller DA. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg. 2010;89(3):907–11.PubMedCrossRef

22.

Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117(1):54–63. discussion 63–55.PubMedCrossRef

23.

Ceresoli GL, Locati LD, Ferreri AJ, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 2001;34(2):279–87.PubMedCrossRef

24.

Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg. 2008;6(4):293–7.PubMedCrossRef

25.

Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453–8.PubMedCrossRef

26.

Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405–11.PubMedCrossRef

27.

Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24(10):1561–7.PubMedCrossRef

28.

Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12(6):1156–63.PubMed

29.

Lee JD, Perez S, Wang HJ, Figlin RA, Holmes EC. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. J Surg Oncol. 1995;60(4):262–7.PubMedCrossRef

30.

van Ruth S, Baas P, Haas RL, Rutgers EJ, Verwaal VJ, Zoetmulder FA. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol. 2003;10(2):176–82.PubMedCrossRef

31.

Kotsakis A, Georgoulias V. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010;11(14):2363–89.PubMedCrossRef

32.

Govindan R, Kratzke RA, Herndon 2nd JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11(6):2300–4.PubMedCrossRef

33.

Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25(17):2406–13.PubMedCrossRef

34.

Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J. 1982;61(26):1007–9.PubMed

35.

Gregoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adhes Migrat. 2010;4(1):153–61.CrossRef

36.

Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology. 2005;10(5):649–55.PubMedCrossRef

37.

Ak G, Metintas M, Yildirim H, et al. Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients. Tüberk Toraks. 2009;57(1):22–31.PubMed

38.

Murthy SC, Okereke I, Mason DP, Rice TW. A simple solution for complicated pleural effusions. J Thorac Oncol. 2006;1(7):697–700.PubMedCrossRef

39.

Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362–8.PubMedCrossRef

Title: Malignant Pleural Mesothelioma
Authors: Siva Raja
Sudish C. Murthy
David P. Mason
Publication date: 01-08-2011
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 4/2011
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-011-0177-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Emerging Therapeutic Targets for Soft Tissue Sarcoma

The Challenges of Providing Palliative Care for Older People with Dementia

Can We Overcome the Effect of Conflicts in Rendering Palliative Care? An Introduction to the Middle Eastern Cancer Consortium (MECC)

Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients

The Value of Data Collection within a Palliative Care Program

Keynote webinar | Spotlight on antibody–drug conjugates in cancer